Clinical experience with adalimumab in a multicenter swiss cohort of patients with crohn's disease

Digestion

Volumn 81, Issue 2, 2010, Pages 78-85

  Nichita, Cristina ^a   Stelle, Marc ^a   Vavricka, Stephan ^b   El Wafa Ali, Abdou ^c   Ballabeni, Pierluigi ^d   De Saussure, Philippe ^e   Straumann, Alex ^f   Rogler, Gerhard ^b   Michetti, Pierre ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Division of Infectious Diseases Pourtalès Hospital   (Switzerland)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f NONE   (Switzerland)

Author keywords

Adalimumab; Crohn's disease; Remission, Crohn's disease; Response, adalimumab

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

ADULT; ARTICLE; ASTHENIA; CLINICAL PRACTICE; COHORT ANALYSIS; CROHN DISEASE; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GYNECOLOGIC DISEASE; HEADACHE; HERPES LABIALIS; HUMAN; INFECTION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; PERIANAL ABSCESS; PHLEBITIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; RASH; REMISSION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; PHENOTYPE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SMOKING; SWITZERLAND; TREATMENT OUTCOME;

EID: 77950853756     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000253855     Document Type: Article

References (22)

1. Targan SR, Hanauer SB, van Deventer SJ, et al: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 15: 1029-1035.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al; ACCENT I Study Group: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549. (Pubitemid 34621118)
3. Present DH, Rutgeerts P, Targan S, et al: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405. (Pubitemid 29205403)
4. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ: Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885. (Pubitemid 38252535)
5. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P: Intravenous hydrocortisone premedication reduced antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-924. (Pubitemid 36389794)
6. Baert F, Noman M, Vermeire S, et al: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608. (Pubitemid 36204954)
7. Hanauer SB, Wagner CL, Bala M, et al: Incidence and importance of antibody response to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-553. (Pubitemid 38834038)
8. Hanauer SB, Sandborn WJ, Rutgeerts P, et al: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333.
9. Sandborn WJ, Hanauer SB, Rutgeerts P, et al: Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-1239. (Pubitemid 47300424)
10. Colombel JF, Sandborn WJ, Rutgeerts P, et al: Adalimumab is effective in maintenance of clinical response and remission in patients with active Crohn's disease: results of the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
11. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al: Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-838. (Pubitemid 351650483)
12. Ho GT, Smith L, Lee HM, Ting T, Fennell J, et al: The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther 2008; 27: 308-315.
13. Hinojosa J, Gomollon F, Garcia S, Bastidas G, et al: Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicenter trial. Aliment Pharmacol Ther 2007; 25: 409-418. (Pubitemid 46184454)
14. Oussalah A, Babouri A, Chevaux JB, et al: Adalimumab for Crohn's disease with intolerance or lost response to infliximab : a 3- year single-centre experience. Aliment Pharmacol Ther 2009; 29: 416-423.
15. Swaminath A, Ullman T, Rosen M, Mayer L, Lichtiger S, Abreu MT: Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximabtreated and naïve patients. Aliment Pharmacol Ther 2009; 29: 273-278.
16. Lofberg R, Louis E, Reinisch W, Kron M, Camez A, Pollack PF: Response to adalimumab in bionaive and anti-TNF-exposed patients with Crohn's disease: results of a phase IIIb clinical trial (poster 721). UEGW 2008, Vienna.
17. Reinisch W, Lofberg R, Louis E, Kron M, Camez A, Pollack PF: Influence of concomitant steroids and immunosuppressant on response to adalimumab in Crohn's disease: results from the CARE study (poster 720). UEGW 2008, Vienna.
18. Harvey RF, Bradshaw JM: A simple index of Crohn's-disease activity. Lancet 1980; 1: 514.
19. Vermeire S, Schreiber S, Sandborn WJ, Bashir SA, Rutgeerts P: Determination of Harvey-Bradshaw definitions for response and remission using the Crohn's Disease Activity Index date from PRECiSE 1 and PRECiSE 2 (poster T1280). DDW 2007, Washington.
20. Sandborn WJ, Colombel JF, Rutgeerts P, Pollack PF, Chao J, Mulani P: Benefits of dosage adjustment with adalimumab in Crohn's disease: an analysis of the CHARM trial (poster). DDW 2008, San Diego.
21. Sandborn WJ, Hanauer SB, Panaccione R, Rutgeerts P, Pollack P: Adalimumab, a human anti-TNF-α monoclonal antibody, induces clinical remission and response in patients with moderate to severely active Crohn's disease irrespective of smoking status (poster). ACG Annual Scientific Meeting, 2004.
22. Colombel JF, Panaccione R, Sandborn WJ, Rutgeers P, Hanauer SB, Reinisch W, Pollack PF, Kent JD, Cardoso AT, Lau W: Global safety of adalimumab in Crohn's disease clinical trials (poster). DDW 2008.